OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, today announced that the Company will host a Key Opinion Leader (KOL) Symposium focused on the potential of TAVO™ (tavokinogene telseplasmid), its lead immunotherapy investigational product candidate, on Friday, April 5, 2019 at 8:00 a.m. ET in New York City.
March 27, 2019
· 3 min read